high
preval
type
diabet
mellitu
world
well
increas
report
advers
side
effect
exist
diabet
treatment
drug
made
develop
new
effect
drug
diseas
high
prioriti
studi
report
ten
novel
compound
found
target
peroxisom
proliferatoractiv
receptor
ppar
use
virtual
screen
core
hop
approach
ppar
drawn
increas
attent
develop
novel
drug
treat
diabet
due
uniqu
function
regul
glucos
lipid
cholesterol
metabol
report
compound
featur
dual
function
henc
belong
categori
dual
agonist
compar
singl
ppar
agonist
dual
ppar
agonist
form
combin
lipid
benefit
agonist
fibrat
glycem
advantag
agonist
thiazolidinedion
much
power
treat
diabet
enhanc
metabol
effect
minim
side
effect
observ
studi
molecular
dynam
simul
well
absorpt
distribut
metabol
excret
novel
dual
agonist
possess
function
ragaglitazar
investig
drug
develop
novo
nordisk
treat
type
diabet
activ
also
favor
conform
bind
two
receptor
moreov
residu
involv
form
bind
pocket
among
top
ten
compound
explicitli
present
use
indepth
conduct
mutagenesi
experi
anticip
ten
compound
may
becom
potenti
drug
candid
least
find
report
may
stimul
new
strategi
provid
use
insight
design
new
power
dualagonist
drug
treat
type
diabet
type
diabet
mellitu
common
type
diabet
mellitu
character
insulin
resist
combin
rel
reduc
insulin
secret
chronic
metabol
diseas
affect
bodi
abil
turn
food
energi
peopl
develop
may
suffer
blind
renal
failur
coronari
arteri
diseas
forth
dramat
increas
worldwid
reach
epidem
scale
anticip
affect
million
peopl
belong
nuclear
hormon
receptor
famili
peroxisom
proliferatoractiv
receptor
ppar
ligandactiv
transcript
factor
ppar
particularli
subtyp
play
central
role
regul
express
gene
involv
control
lipid
lipoprotein
metabol
glucos
homeostasi
inflammatori
process
accordingli
activ
receptor
becom
promis
therapeut
strategi
design
drug
activ
receptor
benef
icial
effect
lipid
metabol
regul
gene
fatti
acid
cholesterol
metabol
agonist
belong
class
lipidlow
drug
fenofibr
gemfibrozil
wide
prescrib
reduc
triglycerid
receptor
wide
studi
subtyp
ppar
locat
adipocyt
muscl
macrophag
direct
influenc
dyslipidemia
atherosclerosi
cardiovascular
diseas
thiazolidinedion
class
agonist
use
clinic
practic
reduc
plasma
glucos
level
type
diabet
patient
regul
glucos
homeostasi
increas
insulin
sensit
glucos
dispos
unfortun
drug
use
alon
undesir
side
effect
weight
gain
edema
anemia
would
caus
therefor
urgent
challeng
task
develop
new
dual
agonist
regard
novel
dual
agonist
form
combin
lipid
benefit
agonist
fibrat
glycem
advantag
agonist
thiazolidinedion
drawn
consider
attent
develop
dual
agonist
critic
problem
surround
identifi
select
ratio
receptor
subtyp
may
provid
use
insight
find
new
drug
candid
inform
avail
design
potenti
dual
treatment
treat
mani
studi
indic
comput
approach
structur
bioinformat
molecular
dock
pharmacophor
model
quantit
structureact
relationship
qsar
techniqu
seri
userfriendli
web
server
predictor
develop
recent
gproteincoupl
receptorsgrey
incid
degre
analysi
gpcrgia
gproteincoupl
receptor
predictor
identifi
g
proteincoupl
receptor
type
iloceuk
ilochum
predict
subcellular
local
eukaryot
human
protein
identifi
nuclear
receptor
subfamili
protid
identifi
proteas
type
hivcleav
predict
human
immunodefici
viru
proteas
cleavag
site
protein
provid
time
use
inform
well
insight
drug
develop
addit
aforement
approach
virtual
screen
techniqu
core
hop
techniqu
also
use
former
use
screen
novel
molecular
scaffold
latter
use
gener
new
lead
compound
improv
core
properti
encourag
aforement
success
studi
present
studi
initi
attempt
screen
fragment
databas
hope
find
new
antidiabet
compound
meanwhil
techniqu
core
hop
associ
glide
dock
molecular
dynam
simul
util
analyz
bind
interact
agonist
ppar
absorpt
distribut
metabol
excret
adm
predict
also
use
evalu
whether
new
agonist
found
date
possess
great
potenti
becom
promis
drug
candid
treat
diabet
mellitu
repres
complex
crystal
structur
protein
data
bank
pdb
id
pdb
id
download
pdb
use
molecular
model
studi
calcul
oper
softwar
packag
version
llc
new
york
ny
usa
run
dell
comput
dell
round
rock
tx
usa
molecular
dynam
simul
perform
use
gromac
packag
wwwgromacscom
linux
system
download
crystal
structur
protein
data
bank
use
receptor
current
model
reason
behind
select
two
protein
two
protein
contain
ligand
use
easili
identifi
bind
site
comparison
resolut
two
crystal
structur
quit
similar
one
pdb
sourc
organ
structur
human
proteinligand
bind
site
identifi
sitemap
tool
embed
schroding
suit
llc
describ
previous
bind
site
encompass
ligand
observ
crystal
structur
bind
site
ppar
compos
three
arm
arm
arm
arm
mark
panel
b
figur
three
segment
play
import
role
interact
receptor
ligand
sever
hydrophob
interact
three
arm
yshape
ligand
deem
key
point
design
new
ppar
agonist
submit
manuscript
wwwdovepresscom
arm
predomin
polar
charact
includ
shown
purpl
ribbon
figur
respons
function
transcript
activ
vital
conform
could
gener
charg
clamp
form
network
hydrogen
bond
thu
significantli
reduc
mobil
regul
gene
express
hydrophob
tail
agonist
interact
either
arm
arm
improv
bind
affin
lead
compound
fragment
databas
deriv
zinc
shoichet
laboratori
depart
pharmaceut
chemistri
univers
california
san
francisco
ca
usa
use
virtual
screen
core
hop
search
describ
respect
zinc
shoichet
librari
depart
pharmaceut
chemistri
univers
california
free
databas
commerci
avail
compound
contain
million
purchas
compound
threedimension
format
lead
compound
leadnow
databas
one
subdatabas
zinc
chosen
virtual
screen
find
optim
molecular
scaffold
dock
program
llc
interfac
suit
llc
prepar
refin
protocol
protein
receptor
compound
structur
perform
protein
prepar
wizard
ligprep
modul
embed
suit
llc
respect
protein
prepar
process
includ
assign
bond
order
ad
hydrogen
treat
metal
treat
disulfid
delet
water
allevi
potenti
steric
hindranc
adjust
bond
order
assign
formal
charg
protein
minim
forc
field
constrain
refin
valu
rmsd
root
mean
squar
deviat
protein
limit
meanwhil
compound
databas
prepar
consist
gener
possibl
state
ioniz
target
ph
desalt
retain
specifi
chiral
threedimension
structur
complet
geometri
minim
forc
field
step
accomplish
investig
compound
dock
receptor
pocket
rigid
dock
model
high
throughput
virtual
screen
score
function
estim
bind
affin
molecular
dock
core
hop
method
mani
use
insight
drug
design
could
gain
conduct
molecular
dock
studi
studi
new
dock
algorithm
call
core
hop
employ
core
hop
offer
function
abl
perform
fragmentbas
replac
molecular
dock
make
power
cuttingedg
techniqu
de
novo
drug
design
allow
rapidli
screen
novel
core
help
overcom
unwant
properti
gener
new
lead
compound
improv
core
properti
demonstr
seri
previou
studi
procedur
core
hop
comput
briefli
describ
follow
first
step
defin
possibl
point
core
attach
could
done
use
program
defin
combin
combinatori
screen
panel
schroding
llc
second
step
defin
receptor
grid
file
could
done
receptor
prepar
panel
third
step
core
prepar
could
done
oper
protocor
prepar
modul
find
core
attach
scaffold
use
fragment
databas
deriv
zinc
fourth
step
align
dock
entir
molecular
structur
built
core
scaffold
four
step
accomplish
investig
compound
redock
receptor
pocket
via
rigid
protein
bind
pocket
defin
residu
least
one
heavi
atom
within
distanc
ligand
carbon
atom
ragaglitazar
black
carbon
atom
comp
gray
overlap
part
ragaglitazar
comp
part
comp
cover
ragaglitazar
mani
marvel
biolog
function
protein
deoxyribonucl
acid
dna
profound
dynam
mechan
switch
activ
inact
state
cooper
effect
alloster
transit
intercal
drug
dna
assembl
microtubul
reveal
studi
intern
motion
likewis
realli
understand
interact
mechan
receptor
ligand
consid
static
structur
concern
also
dynam
inform
obtain
simul
intern
motion
dynam
process
examin
whether
design
agonist
remain
bound
explicit
solvent
dynam
point
view
molecular
dynam
simul
perform
period
boundari
condit
use
gromac
packag
gromac
forc
field
protein
topolog
file
charg
ligand
atom
gener
dunde
server
beta
start
simul
system
solvat
explicit
water
flexibl
simpl
point
charg
model
cubic
box
condit
surfac
protein
cover
water
shell
nm
nanomet
meter
minimum
number
sodium
chlorid
ion
need
balanc
system
charg
place
randomli
solvat
system
subsequ
energi
minim
perform
complex
system
use
steepest
descent
method
ns
second
md
simul
carri
time
step
fs
femtosecond
second
correspond
coordin
store
everi
picosecond
second
particl
mesh
ewald
algorithm
use
calcul
electrostat
interact
simul
run
period
boundari
condit
normal
pressur
temperatur
npt
ensembl
use
berenson
coupl
algorithm
keep
temperatur
k
pressur
atm
bond
constrain
use
linear
constraint
solver
algorithm
adm
predict
adm
use
program
elimin
unfavor
compound
undesir
properti
earli
stage
drug
develop
via
evalu
propos
structur
refin
prior
expens
synthesi
incorpor
adm
predict
part
drug
develop
process
gener
lead
compound
like
exhibit
satisfactori
adm
perform
clinic
trial
program
qikprop
embed
llc
quick
accur
easytous
program
predict
adm
properti
compound
qikprop
program
adopt
featur
function
predict
total
properti
compound
includ
princip
descriptor
physiochem
properti
investig
compound
need
neutral
use
qikprop
automat
done
qikprop
normal
mode
predict
qikprop
use
studi
properti
analysi
molecular
weight
partit
coeffici
qp
logp
ow
predict
aqueou
solubl
qp
log
addit
appar
pmdck
permeabl
qpp
mdck
comput
qikprop
program
evalu
whether
compound
hold
potenti
becom
drug
candid
virtual
screen
core
hop
detail
procedur
discov
desir
dual
agonist
shown
figur
leadnow
databas
zinc
screen
util
softwar
optim
perform
target
ppar
receptor
top
hit
see
figur
select
optim
lead
compound
modif
accord
well
known
structur
ragaglitazar
shown
figur
consequ
phenyl
group
render
red
color
see
figur
modifi
acid
group
color
blue
shown
comp
figur
function
acid
group
also
exit
follow
structur
muraglitazar
faraglitazar
new
molecul
comp
design
intent
stronger
affin
subsequ
core
hop
method
use
search
fragment
databas
desir
chemic
group
replac
amid
group
ie
r
group
figur
help
lengthen
comp
structur
make
better
fit
roomi
space
arm
see
figur
result
amid
group
ie
r
group
comp
figur
replac
best
ten
r
group
ie
r
r
mark
right
side
figur
subsequ
use
gener
whole
molecul
ie
comp
comp
core
hop
approach
see
figur
ten
compound
display
chiral
center
submit
manuscript
wwwdovepresscom
dovepress
dovepress
carbon
atom
acid
group
ragaglitazar
see
figur
compound
comp
comp
prefer
chiral
center
r
group
allow
match
activ
pocket
strategi
studi
similar
previou
paper
howev
start
point
studi
carri
differ
current
studi
use
virtual
screen
first
oper
find
novel
scaffold
ppar
also
use
previou
studi
purpos
develop
new
compound
core
hop
method
previou
studi
mainli
modifi
well
known
ligand
though
use
two
step
core
hop
method
first
glanc
current
studi
quit
similar
previou
studi
use
protein
target
fragment
databas
core
hop
method
molecular
dynam
model
detail
approach
complet
differ
therefor
necessari
combin
studi
use
core
hop
method
novel
drug
develop
order
provid
comprehens
inform
best
ten
potenti
lead
compound
candid
obtain
via
step
redock
two
receptor
respect
shown
panel
b
figur
best
dock
pose
ten
compound
superpos
togeth
activ
pocket
two
receptor
respect
dock
simul
result
seen
compound
form
good
steric
complementar
hydrophob
pocket
receptor
produc
strong
van
der
waal
contact
hydrophob
interact
shown
black
panel
c
figur
ragaglitazar
novel
dual
agonist
also
includ
import
polar
acid
head
group
structur
chosen
posit
control
high
affin
receptor
previou
research
list
tabl
top
ten
compound
ie
comp
comp
much
stronger
ragaglitazar
comp
bind
two
receptor
rank
roughli
accord
dock
score
receptor
best
dock
conform
comp
carbon
atom
color
gray
ragaglitazar
carbon
atom
color
black
align
togeth
panel
c
figur
result
receptorligand
interact
obtain
dock
simul
prove
key
residu
bind
interact
comp
receptor
fulli
consist
previou
report
conserv
hbond
network
form
polar
acid
head
group
ragaglitazar
comp
four
key
residu
observ
dock
simul
noteworthi
comp
three
oxygen
atom
serv
polar
acid
head
allow
comp
opportun
interact
addit
one
hbond
form
oxygen
atom
group
residu
receptor
observ
studi
hbond
network
made
major
contribut
stabil
activ
conform
arm
extraordinarili
import
regul
gene
express
hydrophob
part
comp
deriv
play
import
role
complement
hydrophob
arm
form
hydrophob
residu
shown
light
green
surfac
see
panel
c
figur
compar
ragaglitazar
comp
compound
extra
hydrophob
part
make
fit
hydrophob
arm
henc
result
much
better
bind
affin
ragaglitazar
clearli
indic
dock
score
shown
tabl
illustr
show
gener
best
ten
compound
structur
core
hop
method
note
top
hit
compound
screen
leadnow
databas
select
potenti
lead
compound
modif
accord
vital
import
acid
head
ligand
base
new
molecul
comp
design
shown
left
bottom
subsequ
core
hop
method
use
search
fragment
databas
replac
amid
group
ie
r
group
best
ten
r
group
ie
r
r
shown
right
side
figur
submit
manuscript
wwwdovepresscom
tabl
compound
ragaglitazar
use
posit
control
ten
compound
comp
rank
roughli
accord
dock
score
receptor
note
list
also
correspond
physiochem
descriptor
calcul
qp
simul
van
der
waal
surfac
area
polar
nitrogen
oxygen
atom
accept
region
b
predict
octanolwat
partit
coeffici
accept
region
c
predict
aqueou
solubl
mol
dm
concentr
solut
satur
solut
equilibrium
crystallin
solid
accept
region
predict
appar
cell
permeabl
nmsecond
cell
model
gutblood
barrier
qikprop
predict
nonact
transport
result
poor
e
predict
percent
human
oral
absorpt
scale
predict
base
quantit
multipl
linear
regress
model
properti
usual
correl
well
human
oral
absorpt
result
poor
f
comp
initi
structur
core
hop
design
intent
make
stronger
affin
see
bottom
left
figur
structur
abbrevi
peroxisom
proliferatoractiv
receptoralpha
peroxisom
proliferatoractiv
receptorgamma
adm
absorpt
distribut
metabol
excret
psa
polar
surfac
area
qp
qikprop
acquir
relev
inform
dynam
point
view
ns
molecular
dynam
simul
carri
respect
crystal
structur
well
complex
ragaglitazar
comp
see
figur
charact
concern
reach
simul
equilibrium
within
ns
rmsd
initi
conform
major
criterion
use
evalu
stabil
protein
system
shown
panel
b
figur
backbon
rmsd
curv
interest
see
rmsd
valu
remark
smaller
indic
complex
stabl
order
perform
indepth
studi
interact
helix
agonist
figur
root
mean
squar
fluctuat
sidechain
atom
receptor
also
comput
shown
panel
c
figur
seen
figur
sidechain
root
mean
squar
fluctuat
similar
respect
particularli
true
residu
residu
see
gray
frame
box
mark
panel
c
figur
indic
new
design
comp
like
perform
exactli
function
activ
helix
compound
ragaglitazar
also
list
tabl
correspond
adm
properti
directli
relev
pharmaceut
potenti
seen
tabl
compar
ragaglitazar
predict
adm
properti
polar
surfac
area
logpow
log
ppcaco
percent
human
oral
absorpt
newli
design
agonist
either
much
better
quit
close
ragaglitazar
actual
percentag
within
accept
rang
human
indic
ten
compound
found
studi
particularli
definit
bind
pocket
use
studi
residu
mark
asterisk
key
residu
form
hbond
network
shown
figur
abbrevi
peroxisom
proliferatoractiv
receptoralpha
peroxisom
proliferatoractiv
receptorgamma
comp
compound
hold
high
potenti
becom
new
drug
candid
drug
design
particularli
conduct
mutagenesi
studi
inform
bind
pocket
target
receptor
ligand
crucial
import
accord
previou
studi
bind
pocket
defin
residu
receptor
least
one
heavi
atom
ie
atom
hydrogen
distanc
heavi
atom
ligand
similar
criteria
also
use
defin
bind
pocket
mani
receptorligand
interact
criterion
use
previou
studi
also
use
studi
defin
bind
pocket
receptor
ligand
point
view
residu
involv
form
bind
pocket
dock
ligand
comp
list
tabl
ident
nine
compound
mark
asterisk
key
residu
form
hbond
network
shown
figur
submit
manuscript
http
wwwdovepresscomdrugdesigndevelopmentandtherapyjourn
drug
design
develop
therapi
intern
peerreview
openaccess
journal
span
spectrum
drug
design
develop
clinic
applic
clinic
outcom
patient
safeti
program
develop
effect
safe
sustain
use
medicin
featur
journal
also
accept
index
pubm
central
manuscript
manag
system
complet
onlin
includ
quick
fair
peerreview
system
easi
use
